Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000;44(4):236-41.
doi: 10.1159/000008243.

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

M Farlow  1 , R Anand, J Messina Jr, R Hartman, J Veach
Affiliations
Clinical Trial

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

M Farlow et al. Eur Neurol. 2000.

Abstract

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.

PubMed Disclaimer

Comment in

Publication types

MeSH terms

LinkOut - more resources